43 related articles for article (PubMed ID: 16269457)
21. Intermedin functions as a pituitary paracrine factor regulating prolactin release.
Lin Chang C; Roh J; Park JI; Klein C; Cushman N; Haberberger RV; Hsu SY
Mol Endocrinol; 2005 Nov; 19(11):2824-38. PubMed ID: 16002435
[TBL] [Abstract][Full Text] [Related]
22. Stress hormone secretion is altered by central administration of intermedin/adrenomedullin-2.
Taylor MM; Samson WK
Brain Res; 2005 May; 1045(1-2):199-205. PubMed ID: 15910778
[TBL] [Abstract][Full Text] [Related]
23. Intermedin/adrenomedullin-2 acts within central nervous system to elevate blood pressure and inhibit food and water intake.
Taylor MM; Bagley SL; Samson WK
Am J Physiol Regul Integr Comp Physiol; 2005 Apr; 288(4):R919-27. PubMed ID: 15576658
[TBL] [Abstract][Full Text] [Related]
24. Central neuropeptide B administration activates stress hormone secretion and stimulates feeding in male rats.
Samson WK; Baker JR; Samson CK; Samson HW; Taylor MM
J Neuroendocrinol; 2004 Oct; 16(10):842-9. PubMed ID: 15500544
[TBL] [Abstract][Full Text] [Related]
25. Neuropeptide W acts in brain to control prolactin, corticosterone, and growth hormone release.
Baker JR; Cardinal K; Bober C; Taylor MM; Samson WK
Endocrinology; 2003 Jul; 144(7):2816-21. PubMed ID: 12810535
[TBL] [Abstract][Full Text] [Related]
26. Protective effects of intermedin on cardiovascular, pulmonary and renal diseases: comparison with adrenomedullin and CGRP.
Holmes D; Campbell M; Harbinson M; Bell D
Curr Protein Pept Sci; 2013 Jun; 14(4):294-329. PubMed ID: 23745696
[TBL] [Abstract][Full Text] [Related]
27. Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.
Bell D; McDermott BJ
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S247-62. PubMed ID: 17965749
[TBL] [Abstract][Full Text] [Related]
28. Multi-biological functions of intermedin in diseases.
Yang Z; Li H; Wu P; Li Q; Yu C; Wang D; Li W
Front Physiol; 2023; 14():1233073. PubMed ID: 37745233
[TBL] [Abstract][Full Text] [Related]
29. Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases.
Zhang SY; Xu MJ; Wang X
Br J Pharmacol; 2018 Apr; 175(8):1230-1240. PubMed ID: 28407200
[TBL] [Abstract][Full Text] [Related]
30. The Cardiopulmonary Effects of the
Tellİ G; Tel BC; GÜmÜŞel B
Turk J Pharm Sci; 2020 Jun; 17(3):349-356. PubMed ID: 32636714
[TBL] [Abstract][Full Text] [Related]
31. Intermedin/Adrenomedullin-2 inhibits growth hormone release from cultured, primary anterior pituitary cells.
Taylor MM; Bagley SL; Samson WK
Endocrinology; 2006 Feb; 147(2):859-64. PubMed ID: 16269457
[TBL] [Abstract][Full Text] [Related]
32. Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis.
Takahashi K; Morimoto R; Hirose T; Satoh F; Totsune K
J Mol Neurosci; 2011 Feb; 43(2):182-92. PubMed ID: 20596793
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
